Pharming Group N.V. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PHAR Nasdaq 2830 www.pharming.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pharming Group N.V.

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference - Aug 4th, 2026 12:00 am
Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results - Aug 2nd, 2026 6:15 pm
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ... - Jul 30th, 2026 1:04 pm
Pharming Group Q2 Earnings Call Highlights - Jul 30th, 2026 7:04 am
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use - Jul 29th, 2026 11:00 pm
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30 - Jul 16th, 2026 12:00 am
Pharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth Case - Jun 27th, 2026 7:08 am
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Jun 15th, 2026 5:59 am
High Growth Tech Stocks in Europe with Promising Potential - Jun 4th, 2026 11:38 pm
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS - Jun 3rd, 2026 11:00 pm
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York - Jun 2nd, 2026 12:00 am
Pharming Group announces results of 2026 Annual General Meeting of Shareholders - May 28th, 2026 8:40 am
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union - May 22nd, 2026 1:30 pm
We Think Pharming Group's (AMS:PHARM) Profit Is Only A Baseline For What They Can Achieve - May 14th, 2026 12:09 am
Pharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their Models - May 10th, 2026 10:04 pm
Pharming Group Q1 Earnings Call Highlights - May 8th, 2026 1:12 pm
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders - May 6th, 2026 11:05 pm
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - May 6th, 2026 11:00 pm
High Growth Tech Stocks To Watch In May 2026 - May 5th, 2026 3:38 am
Pharming Group to report first quarter 2026 financial results and provide business update on May 7 - Apr 23rd, 2026 12:00 am